Grant: Project Grant - PA: Breast Cancer Research
University of British Columbia
$100,000.00
Podocalyxin's role in tumor invasion, metastasis, and immune evasion
FY 2022-23
Summary
We have developed two promising monoclonal antibodies (mAbs) for the treatment of human cancers. These mAbs both target a protein expressed in a subset of highly aggressive tumors in ovarian, breast and pancreatic cancers (among others) called podocalyxin (PODXL). One mAb (PODO83) blocks the invasion and spread of tumors. The other mAb (PODO447) only binds tumors and can be used to target toxins to cancer cells while avoiding harm to normal tissue. We think that the place on the PODXL protein that these mAbs target (domains) have important roles in making tumor cells more aggressive and harder to treat. We propose to use these mAbs to better understand how PODXL promotes aggressive tumor behaviour. Our research will allow us to more effectively apply our mAbs for immunotherapy in patients that do not have other treatment options and also to discover new treatment approaches.
Department
Program
Project Grant - PA: Breast Cancer Research
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
472389
Name
McNagny Kelly M
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Cancer Biology & Therapeutics
Projecttitle
Podocalyxin's role in tumor invasion, metastasis, and immune evasion
Programtype2
Operating Grants
Orgnameinp2
University of British Columbia
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Project Grant - PA: Breast Cancer Research
Keyworddelim
Breast Cancer; Cancer Therapy; Glycosylation; Immunolgy; Invasion; Metastasis; Ovarian/Fallopian Tube Cancer; Podocalyxin; Trangenic Mice; Tumor Stem Cells
Abstract
We have developed two promising monoclonal antibodies (mAbs) for the treatment of human cancers. These mAbs both target a protein expressed in a subset of highly aggressive tumors in ovarian, breast and pancreatic cancers (among others) called podocalyxin (PODXL). One mAb (PODO83) blocks the invasion and spread of tumors. The other mAb (PODO447) only binds tumors and can be used to target toxins to cancer cells while avoiding harm to normal tissue. We think that the place on the PODXL protein that these mAbs target (domains) have important roles in making tumor cells more aggressive and harder to treat. We propose to use these mAbs to better understand how PODXL promotes aggressive tumor behaviour. Our research will allow us to more effectively apply our mAbs for immunotherapy in patients that do not have other treatment options and also to discover new treatment approaches.
Competitiondate
202209
Approvedterm2
1 yr 0 mth
Pinamesdelim
McNagny, Kelly M; Roskelley, Calvin D
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~
